Prolight Diagnostics publishes quarterly report Q1, 2025
Financial overview First quarter, January 1 – March 31, Q1 2025 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to 1,662 (68) thousand SEK. Profit after tax amounted to -10,937 (-8,929) thousand SEK. Earnings per share before and after dilution: -0.02 […]
NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), corp. reg. no. 556570-9499, (the ”Company”) are hereby notified of the annual general meeting to be held on Monday 30 June 2025 at 1 p.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification of attendance Shareholders who wish to participate in the annual general […]
NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), reg. no. 556570-9499, (the ”Company”) are hereby convened to the extraordinary general meeting to be held on Tuesday 10 June 2025 at 10 a.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification etc.Shareholders who wish to participate in the extraordinary general meeting must:– be […]
Prolight has resolved on a rights issue of shares to complete the development of the Point of Care system Psyros™ and reach commercialisation
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The […]
Prolight announces positive pre-clinical data
Prolight Diagnostics today announces positive results from the company’s pre-clinical validation study using plasma biobank samples. The results demonstrate that Prolight is on track to deliver its high-sensitivity troponin assay on the Psyros™ single-molecule-counting system. “The study results are highly encouraging and affirm the performance underlying the Psyros technology. Our system demonstrated very good clinical sensitivity […]
Prolight Diagnostics publishes year-end report 2024
Financial overview(figures in parentheses refer to the corresponding period in the previous year) Fourth quarter, October 1 – December 31, Q4 2024 Group• Net sales amounted to 0 (0).• Other operating income amounted to 15,317 (11,580) TSEK.• Profit after tax amounted to 2,011 (-110,094) TSEK.• Earnings per share before and after dilution: 0.00 (-0.32) SEK.• […]
The nomination committee appointed for the Annual General Meeting 2025.
The nomination committee is appointed in consultation with the three largest shareholders or owner groups, according to the number of votes based on shareholder statistics from Euroclear Sweden, and other reliable owner information in accordance with the decision of the Annual General Meeting. The nomination committee’s task is to produce proposals for the AGM regarding […]
Prolight Diagnostics publishes quarterly report Q3, 2024
Financial overviewThird quarter, 1 July – 30 September, Q3 2024 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to SEK 3,730 (28) thousand. The profit after tax amounted to SEK -8,795 (-9,755) thousand. Earnings per share before and after dilution: -0.01 […]
Warrants of series TO7 were exercised to approximately 96.4 percent and Prolight Diagnostics receives approximately SEK 12.6 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Last day of trading with warrants of series TO7 in Prolight Diagnostics is today, October 15, 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
